Platomics offers a cloud software platform that automates the analysis of genetic tests and bundles the certification labs will need to comply with the EU IVDR rules (effective from 2022). The product targets laboratories that previously developed and ran their own tests and now must meet new EU regulatory standards. Customers pay per gene test to use the analysis software and certification package; exact pricing remains confidential. The software runs on servers hosted in Europe and can be deployed to specific countries (for example, Austria) at the customer's request. The company says it is focusing on commercializing the platform across Europe and has partnerships with leading international reagent manufacturers that support broader market reach. Platomics has grown quietly to about 75 employees and positions itself to serve the personalized-medicine market by ensuring scientifically reliable test results for patients. Founded in 2014 as a spin‑off of the Austrian Institute of Technology, the company emphasizes its regulatory-ready offering as a market differentiator.

Total raised

$16M

Funding rounds

1

Latest round

Series A

Latest activity

Sep 2021